自2014年成立，鹍远生物一直以攻克癌症早期筛查与诊断为目标，公司基于分子诊断技术开发了一系列肿瘤和遗传疾病的基因检测解决方案。作为甲基化检测技术的引领者和推动者，鹍远生物提供高发癌症的风险评估、早筛早诊、用药指导及术后监测的全周期服务。公司拥有丰富的产品管线，覆盖泛癌种、肺癌、结直肠癌、肝癌、胃癌、食道癌、胰腺癌、甲状腺癌等。
Investors 1
| Date | Name | Website |
| - | LAV | lavfund.co... |
Mentions in press and media 1
| Date | Title | Description |
| - | Singlera | “Since its inception in 2014,远远生物生体一直攻克早期早期早期早期早期早期早期目，The company has developed a series of tumor and disease-based detection solutions based on molecular detection technology.As a leader and promoter of a-based detection technology,远 remo... |